Summarized by Masters of Longevity from Neuroscience News.
Reports that a BRAF inhibitor approved for pediatric brain tumors reduced lesion size, leakage, and hemorrhagic progression in preclinical models of fragile cerebral vascular malformations.
Key Takeaways
- Dabrafenib reduced the size and number of CCM lesions in animal models.
- The drug repaired endothelial junctions and lowered vessel leakage and microhemorrhages.
- Repurposing dabrafenib could enable clinical trials as a noninvasive CCM treatment.
